Loading...
•
Mar 31, 2020
Akebia Q1 2020 Earnings Report
Akebia reported positive top-line results from global Phase 3 program of vadadustat for treatment of anemia due to chronic kidney disease in adult patients on dialysis and financial results
Key Takeaways
Akebia Therapeutics, Inc. announced positive top-line results from INNO2VATE and reported financial results for the first quarter ended March 31, 2020. The company's cash runway extends well into 2021.
Vadadustat achieves primary efficacy and cardiovascular safety endpoints.
Company’s cash runway extends well into 2021.
Company announced positive top-line results from INNO2VATE.
Company settled Auryxia patent litigation with Teva Pharmaceuticals USA, Inc. (Teva) and its wholly owned, indirect subsidiary, Watson Laboratories, Inc. (Watson).
Akebia
Akebia
Akebia Revenue by Segment
Revenue by Segment
Auryxia Net Product Revenue
CapyFin.comLicense, Collaboration & Other Revenue
CapyFin.com Forward Guidance
Akebia is focused on supporting patients and executing on its plans to position Akebia for long term growth.